Hypogonadism and androgen replacement therapy in elderly men

被引:106
作者
Basaria, S [1 ]
Dobs, AS [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Div Endocrinol & Metab, Baltimore, MD USA
关键词
D O I
10.1016/S0002-9343(01)00663-5
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The decrease in testosterone levels with age is both central (pituitary) and peripheral (testicular) origin. Because serum levels of sex-hormone-binding globulin increase with aging, the decrease in free testosterone is of even greater magnitude. Recent long-term studies of testosterone therapy in hypogonadal elderly men have shown beneficial effects on bone density, body composition, and muscle strength without any substantial adverse effects on lipids and the prostate. Total testosterone level is the test of choice for initial screening of elderly men who present with signs and symptoms of hypogonadism. If the level is below 300 ng/dL, replacement therapy should be initiated. If the level is normal in a symptomatic patient, free or bioavailable testosterone should be determined. The pros and cons of testosterone therapy should be discussed in depth with every patient, and decisions should be made on an individual basis. This review summarizes the trials of testosterone replacement therapy in elderly men and outlines a diagnostic approach to these patients. (C) 2001 by Excerpta Medica, Inc.
引用
收藏
页码:563 / 572
页数:10
相关论文
共 158 条
[1]
LOW CIRCULATING LEVELS OF INSULIN-LIKE GROWTH-FACTORS AND TESTOSTERONE IN CHRONICALLY INSTITUTIONALIZED ELDERLY MEN [J].
ABBASI, AA ;
DRINKA, PJ ;
MATTSON, DE ;
RUDMAN, D .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1993, 41 (09) :975-982
[2]
Albright F, 1948, PARATHYROID GLANDS M, P145
[3]
Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system [J].
Arver, S ;
Dobs, AS ;
Meikle, AW ;
Allen, RP ;
Sanders, SW ;
Mazer, NA .
JOURNAL OF UROLOGY, 1996, 155 (05) :1604-1608
[4]
Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men [J].
Arver, S ;
Dobs, AS ;
Meikle, AW ;
Caramelli, KE ;
Rajaram, L ;
Sanders, SW ;
Mazer, NA .
CLINICAL ENDOCRINOLOGY, 1997, 47 (06) :727-737
[5]
Drug therapy - Androgens in men - Uses and abuses [J].
Bagatell, CJ ;
Bremner, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (11) :707-714
[6]
ANDROGEN AND PROGESTAGEN EFFECTS ON PLASMA-LIPIDS [J].
BAGATELL, CJ ;
BREMNER, WJ .
PROGRESS IN CARDIOVASCULAR DISEASES, 1995, 38 (03) :255-271
[7]
CHANGES IN ERECTILE RESPONSIVENESS DURING ANDROGEN REPLACEMENT THERAPY [J].
BANCROFT, J ;
WU, FCW .
ARCHIVES OF SEXUAL BEHAVIOR, 1983, 12 (01) :59-66
[8]
Endogenous sex hormones and cognitive function in older men [J].
Barrett-Connor, E ;
Goodman-Gruen, D ;
Patay, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (10) :3681-3685
[9]
Bioavailable testosterone and depressed mood in older men:: The Rancho Bernardo study [J].
Barrett-Connor, E ;
Von Mühlen, DG ;
Kritz-Silverstein, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02) :573-577
[10]
BARRETTCONNOR EL, 1995, DIABETES METAB, V21, P156